Pierre Queiroz de Oliveira is a registered patent agent in the Intellectual Property Practice Group of Pepper Hamilton LLP, resident in the Pittsburgh office.
Dr. Queiroz de Oliveira holds a Ph.D. in molecular pharmacology from the University of Pittsburgh School of Medicine. His research has focused on the development of novel therapeutic agents for the treatment of cancer and the regulation of the mammalian cell cycle in hypoxic tumors. His scientific experience ranges from classical and molecular pharmacology to molecular biology, biochemistry and drug development.
During his tenure at the University of Pittsburgh, Dr. Queiroz de Oliveira was selected as a Fellow in molecular pharmacology and has received recognition for his outstanding research presentations at the University of Pittsburgh and the University of Bath, United Kingdom. Pierre holds a M.S. degree from the University of Bath.
Prior to joining Pepper, Dr. Queiroz de Oliveira was an executive associate at the Pittsburgh Life Science Greenhouse, a life science company formation and capital investment firm. Dr. Queiroz de Oliveira was focused on the therapeutics, diagnostics and medical device segments, assisting early stage companies with business development, fundraising and business, commercial and regulatory strategy.
Dr. Queiroz de Oliveira has been published in a number of peer-reviewed journals and his research has been presented at numerous national meetings. His publications and speaking engagements include:
- “Hypoxia-Mediated Regulation of Cdc25A Phosphatase by p21 and miR-21” (co-author), Cell Cycle, 2009 Oct 1; 8(19):3157-64
- “An Allosteric Inhibitor of Dusp6, Identified From a Zebrafish Chemical Screen, Expands Cardiac Progenitors and Heart Size” (co-author), Nature Chemical Biology, 2009 Sep; 5(9):680-7
- “Supression of Cdc25A by Hypoxia Required the Cell Cycle Inhibitor p21," San Diego, CA, April 11-16, 2008
- “Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non-Small Cell Lung Cancer” (co-author), Molecular Pharmacology, 2007; 72(3):769-79
- “Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma” (co-author), Neoplasia, 2006; 8(11): 949-955
- “Novel Benzofuran Inhibitors of Human Mitogen-Activated Protein Kinase Phosphatase-1” (co-author), Bioorg Med Chem, 2006; 14(16):5643-50
- “Ad-IRF-1 Induces Apoptosis in Esophageal Adenocarcinoma” (co-author), Neoplasia, 2006; 8(1):31-7
- “Altered Trafficking of Fas and Subsequent Resistance to Fas-Mediated Apoptosis Occurs by a Wild-Type p53 Independent Mechanism in Esophageal Adenocarcinoma” (co-author), Journal of Surgical Research, 2005; 123(2):302-11
- “The HGF Receptor c-Met is Overexpressed in Esophageal Adenocarcinoma” (co-author), Neoplasia, 2005; 7(1):75-84
- “Restoration of IRF-1 Expression Induces Cell Death in Esophageal Adenocarcinoma Cells,” Digestive Diseases Week, New Orleans, LA, May 15-20, 2004.
Dr. Queiroz de Oliveira is a member of the American Association for Cancer Research. He is fluent in English, French and Portuguese. Dr. Queiroz de Oliveira is admitted to practice before the U.S. Patent and Trademark Office.